\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\ \(73\)\
\-\ treatment\\/management\\:\\ no\\ known\\ effective\\ cure\\/treatment\\.\\ steroids\\ have\\ not\\ been\\ proven\\ to\\ change\\ course\\ of\\ disease\\ once\\ fibrosis\\ has\\ begun\\.\\ stopping\\ smoking\\ may\\ slow\\ progression\\.\\ neurofibromatosis\\ 1\\ has\\ soft\\ tissue\\ neoplastic\\ tendencies\\ that\\ should\\ be\\ monitored\\ periodically\\ for\\ interval\\ changes\\ if\\ there\\ is\\ suspicision\\ for\\ malignancy\\ or\\ if\\ the\\ patient\\ is\\ symptomatic\\.\ \(0\)\
\-\ cxr\\:\\ ill\\-defined\\ density\\ in\\ upper\\ lateral\\ peri\\-hilar\\ region\\ on\\ pa\\ view\\,\\ not\\ definitively\\ seen\\ on\\ lateral\\ projection\\,\\ but\\ possibly\\ more\\ anterior\\.\ \(0\)\
\-\ ct\\,\\ chest\\ w\\/contrast\\:\\ multiple\\ soft\\ tissue\\ attenuated\\ skin\\ nodules\\ noted\\ on\\ anterior\\ chest\\.\\ no\\ pulmonary\\ nodules\\ or\\ masses\\ seen\\.\\ \\ pulmonary\\ fibrosis\\ with\\ honey\\-combing\\ predominately\\ occurring\\ in\\ the\\ upper\\ lobes\\.\\ bullous\\ changes\\ are\\ seen\\ adjacent\\ to\\ mediastinum\\ near\\ azygoesophageal\\ recess\\.\\ pulmonary\\ scaring\\ and\\ honey\\-combing\\ extends\\ to\\ right\\ lower\\ lung\\.\ \(0\)\
\-\ pulmonary\\ manifestations\\ of\\ neurofibromatosis\\ 1\\.\\ however\\,\\ pulmonary\\ fibrosis\\ with\\ bullous\\ formation\\ from\\ smoking\\ related\\ pulmonary\\ diseases\\ can\\â\\€\\™t\\ be\\ ruled\\ out\\.\ \(0\)\
\-\ emphysema\ \(98\)\
\-\ idiopathic\\ pulmonary\\ fibrosis\\ \\(ipf\\)\ \(0\)\
\-\ autoimmune\\ disorders\\ \\(sarcoidosis\\,\\ ra\\)\ \(0\)\
\-\ collagen\\-vascular\\ diseases\\ with\\ fibrosising\\ aveolitits\ \(0\)\
\-\ 66\\ y\\.o\\.\\ female\\ with\\ nf1\\,\\ vomiting\\,\\ 25\\ pack\\ year\\ smoking\\ history\\,\\ no\\ history\\ of\\ copd\\.\\ \\ cxr\\ obtained\\ initially\\ and\\ chest\\ ct\\ later\\ obtained\\ for\\ further\\ evaluation\\ of\\ cxr\\ findings\\.\ \(0\)\
\-\ dx\\:\\ \\ pulmonary\\ fibrosis\\ with\\ bullous\\ formation\\ consistent\\ with\\ pulmonary\\ manifestations\\ of\\ neurofibromatosis\\ 1\\,\\ however\\,\\ smoking\\ related\\ pulmonary\\ diseases\\ can\\â\\€\\™t\\ be\\ ruled\\ out\\.\ \(0\)\
\-\ disease\\ discussion\\:\\ \\ neurofibromatosis\\ 1\\ \\(von\\ reckinghausen\\â\\€\\™s\\ disease\\,\\ or\\ nf1\\)\\,\\ is\\ a\\ autosomal\\ dominant\\ disorder\\ involving\\ chromosome\\ 17\\ of\\ probable\\ neural\\ crest\\ origin\\ affecting\\ all\\ 3\\ germinal\\ layers\\.\\ \\ considered\\ the\\ most\\ common\\ neurocutanous\\ disorder\\,\\ both\\ neuroectodermal\\ and\\ mesenchymal\\ derivatives\\.\\ \\ typically\\ nf1\\ is\\ recognized\\ on\\ clinical\\ exam\\ \\(85\\%\\ of\\ patients\\)\\ with\\ cutanous\\ neurofibromas\\.\\ \\ nf1\\ can\\ manifest\\ in\\ any\\ organ\\ in\\ the\\ body\\.\\ projection\\ of\\ neurofibromas\\ over\\ the\\ thorax\\ on\\ frontal\\ and\\ lateral\\ radiographs\\ may\\ be\\ misinterpreted\\ as\\ a\\ pulmonary\\ nodule\\ \\(as\\ demonstrated\\ on\\ above\\ cxr\\)\\,\\ so\\ it\\ is\\ important\\ to\\ use\\ ct\\ to\\ help\\ differentiate\\.\ \(0\)\
\-\ pulmonary\\ involvement\\ occurs\\ in\\ 10\\-20\\%\\ of\\ all\\ nf1\\ patients\\.\\ occurring\\ usually\\ not\\ until\\ adult\\ hood\\.\\ the\\ lung\\ parenchyma\\ can\\ progress\\ to\\ developing\\ interstitial\\ fibrosis\\ with\\ associated\\ severe\\ thin\\-walled\\ bullous\\ formations\\ reported\\ to\\ typically\\ occur\\ in\\ the\\ upper\\ lobes\\ and\\ apical\\ segments\\ of\\ the\\ lower\\ lobes\\ bilaterally\\ and\\ symmetrically\\.\\ honey\\-combing\\,\\ also\\ described\\ as\\ subpleural\\ small\\-blister\\-like\\ changes\\,\\ is\\ reportedly\\ seen\\ in\\ the\\ bibasilar\\ regions\\ of\\ the\\ lungs\\.\\ \\ these\\ findings\\ may\\ be\\ coincidental\\ with\\ other\\ lung\\ diseases\\,\\ however\\,\\ the\\ noted\\ mesenchymal\\ abnormalities\\ caused\\ by\\ nf1\\ may\\ affect\\ lung\\ parenchyma\\.\\ \\ the\\ pathology\\ of\\ the\\ lung\\ parenchyma\\ shows\\ alveolar\\ wall\\ thickening\\ progressing\\ to\\ fibrosis\\ and\\ lung\\ destruction\\.\\ pulmonary\\ function\\ tests\\ show\\ either\\ an\\ obstructive\\ or\\ a\\ restrictive\\ process\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ nf1\\:\\ 0\\.07462334819014906\ \(0\)\
\-\ pulmonary\\:\\ 0\\.06747433270865037\ \(0\)\
\-\ bullous\\:\\ 0\\.05992582545972888\ \(0\)\
\-\ fibrosis\\:\\ 0\\.0553725195615212\ \(0\)\
\-\ honey\\-combing\\:\\ 0\\.054982443392722444\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.03926132109558751\ \(0\)\
\-\ smoking\\:\\ 0\\.0358894698847088\ \(0\)\
\-\ diseases\\:\\ 0\\.035797579355090633\ \(0\)\
\-\ lung\\:\\ 0\\.030875165741023863\ \(0\)\
\-\ cxr\\:\\ 0\\.0299877943544705\ \(0\)\
\-\ neurofibromas\\:\\ 0\\.026322710079744273\ \(0\)\
\-\ mesenchymal\\:\\ 0\\.023995825306624013\ \(0\)\
\-\ lobes\\:\\ 0\\.023486459979523668\ \(0\)\
\-\ parenchyma\\:\\ 0\\.022698765226981304\ \(0\)\
\-\ projection\\:\\ 0\\.020646032524974805\ \(0\)\
\-\ manifestations\\:\\ 0\\.020225674450665573\ \(0\)\
\-\ occurring\\:\\ 0\\.01984393827913492\ \(0\)\
\-\ ruled\\:\\ 0\\.01977162334062403\ \(0\)\
\-\ treatment\\/management\\:\\ 0\\.018327481130907482\ \(0\)\
\-\ cure\\/treatment\\:\\ 0\\.018327481130907482\ \(0\)\
\-\ tendencies\\:\\ 0\\.018327481130907482\ \(0\)\
\-\ suspicision\\:\\ 0\\.018327481130907482\ \(0\)\
\-\ peri\\-hilar\\:\\ 0\\.018327481130907482\ \(0\)\
\-\ fibrosising\\:\\ 0\\.018327481130907482\ \(0\)\
\-\ aveolitits\\:\\ 0\\.018327481130907482\ \(0\)\
\-\ reckinghausen\\:\\ 0\\.018327481130907482\ \(0\)\
\-\ neurocutanous\\:\\ 0\\.018327481130907482\ \(0\)\
\-\ cutanous\\:\\ 0\\.018327481130907482\ \(0\)\
\-\ small\\-blister\\-like\\:\\ 0\\.018327481130907482\ \(0\)\
\-\ collagen\\-vascular\\:\\ 0\\.016886426701468928\ \(0\)\
\-\ hood\\:\\ 0\\.016886426701468928\ \(0\)\
\-\ formations\\:\\ 0\\.016886426701468928\ \(0\)\
\-\ t\\:\\ 0\\.016447842077358943\ \(0\)\
\-\ can\\:\\ 0\\.016118273201405985\ \(0\)\
\-\ derivatives\\:\\ 0\\.01604346389874925\ \(0\)\
\-\ disorder\\:\\ 0\\.01596168266755062\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.015929480704649415\ \(0\)\
\-\ may\\:\\ 0\\.015586930302687102\ \(0\)\
\-\ ipf\\:\\ 0\\.01544537227203037\ \(0\)\
\-\ misinterpreted\\:\\ 0\\.01544537227203037\ \(0\)\
\-\ changes\\:\\ 0\\.015274727502505575\ \(0\)\
\-\ azygoesophageal\\:\\ 0\\.01498145636493222\ \(0\)\
\-\ coincidental\\:\\ 0\\.01498145636493222\ \(0\)\
\-\ however\\:\\ 0\\.014840133402892332\ \(0\)\
\-\ nodules\\:\\ 0\\.014729808172152813\ \(0\)\
\-\ formation\\:\\ 0\\.014666325959550783\ \(0\)\
\-\ related\\:\\ 0\\.014666325959550783\ \(0\)\
\-\ scaring\\:\\ 0\\.014602409469310693\ \(0\)\
\-\ seen\\:\\ 0\\.014042641289544203\ \(0\)\
\-\ periodically\\:\\ 0\\.014004317842591815\ \(0\)\
\-\ stopping\\:\\ 0\\.013759446666591017\ \(0\)\
\-\ w\\/contrast\\:\\ 0\\.013759446666591017\ \(0\)\
\-\ be\\:\\ 0\\.013698094837254982\ \(0\)\
\-\ restrictive\\:\\ 0\\.013540401935493664\ \(0\)\
\-\ 10\\-20\\:\\ 0\\.013342251873530412\ \(0\)\
\-\ chromosome\\:\\ 0\\.013161355039872136\ \(0\)\
\-\ begun\\:\\ 0\\.0129949460842099\ \(0\)\
\-\ attenuated\\:\\ 0\\.0129949460842099\ \(0\)\
\-\ germinal\\:\\ 0\\.0129949460842099\ \(0\)\
\-\ thin\\-walled\\:\\ 0\\.0129949460842099\ \(0\)\
\-\ upper\\:\\ 0\\.01286120897319367\ \(0\)\
\-\ chest\\:\\ 0\\.01275298752634627\ \(0\)\
\-\ crest\\:\\ 0\\.012697439132773988\ \(0\)\
\-\ subpleural\\:\\ 0\\.012697439132773988\ \(0\)\
\-\ 1\\:\\ 0\\.012681869238833932\ \(0\)\
\-\ obtained\\:\\ 0\\.012631459878352774\ \(0\)\
\-\ neuroectodermal\\:\\ 0\\.012563263413153258\ \(0\)\
\-\ symmetrically\\:\\ 0\\.012563263413153258\ \(0\)\
\-\ typically\\:\\ 0\\.012542310891916725\ \(0\)\
\-\ manifest\\:\\ 0\\.012205986371725694\ \(0\)\
\-\ recess\\:\\ 0\\.011997912653312006\ \(0\)\
\-\ reportedly\\:\\ 0\\.011808782137291786\ \(0\)\
\-\ \\:\\:\\ 0\\.011749218461441426\ \(0\)\
\-\ out\\:\\ 0\\.011742427762405474\ \(0\)\
\-\ definitively\\:\\ 0\\.011720300610433582\ \(0\)\
\-\ progressing\\:\\ 0\\.011720300610433582\ \(0\)\
\-\ dx\\:\\ 0\\.01163543159895696\ \(0\)\
\-\ lateral\\:\\ 0\\.011517680118240439\ \(0\)\
\-\ bibasilar\\:\\ 0\\.011475429434432785\ \(0\)\
\-\ predominately\\:\\ 0\\.011399821026593128\ \(0\)\
\-\ autoimmune\\:\\ 0\\.01132686609975057\ \(0\)\
\-\ pack\\:\\ 0\\.011256384703335431\ \(0\)\
\-\ von\\:\\ 0\\.011188214593516325\ \(0\)\
\-\ layers\\:\\ 0\\.01105823464137218\ \(0\)\
\-\ recognized\\:\\ 0\\.01105823464137218\ \(0\)\
\-\ monitored\\:\\ 0\\.010710928852051669\ \(0\)\
\-\ copd\\:\\ 0\\.010658293076616553\ \(0\)\
\-\ alveolar\\:\\ 0\\.010606957083705178\ \(0\)\
\-\ differentiate\\:\\ 0\\.0104601430146533\ \(0\)\
\-\ organ\\:\\ 0\\.010413421900615756\ \(0\)\
\-\ autosomal\\:\\ 0\\.010279246180995027\ \(0\)\
\-\ not\\:\\ 0\\.010268762342968278\ \(0\)\
\-\ probable\\:\\ 0\\.010236378640032998\ \(0\)\
\-\ apical\\:\\ 0\\.010236378640032998\ \(0\)\
\-\ affect\\:\\ 0\\.010236378640032998\ \(0\)\
\-\ \\,\\:\\ 0\\.010130522202310132\ \(0\)\
\-\ effective\\:\\ 0\\.010112837225332787\ \(0\)\
\-\ proven\\:\\ 0\\.010112837225332787\ \(0\)\
\-\ thorax\\:\\ 0\\.010073235988387478\ \(0\)\
\-\ all\\:\\ 0\\.010049577918633226\ \(0\)\
\-\ ill\\-defined\\:\\ 0\\.010034375004994229\ \(0\)\
\-\ progress\\:\\ 0\\.010034375004994229\ \(0\)\
\-\ segments\\:\\ 0\\.00999622710755515\ \(0\)\
\-\ 85\\:\\ 0\\.00992196913956746\ \(0\)\
\-\ affecting\\:\\ 0\\.009885811670312016\ \(0\)\
\-\ emphysema\\:\\ 0\\.009713895421153775\ \(0\)\
\-\ ra\\:\\ 0\\.009713895421153775\ \(0\)\
\-\ if\\:\\ 0\\.009641344839004721\ \(0\)\
\-\ slow\\:\\ 0\\.009617180211933623\ \(0\)\
\-\ 66\\:\\ 0\\.009555115839481064\ \(0\)\
\-\ developing\\:\\ 0\\.00929670062809317\ \(0\)\
\-\ tests\\:\\ 0\\.00929670062809317\ \(0\)\
\-\ patients\\:\\ 0\\.009195736379900316\ \(0\)\
\-\ anterior\\:\\ 0\\.009150905712111175\ \(0\)\
\-\ obstructive\\:\\ 0\\.009140702320519544\ \(0\)\
\-\ once\\:\\ 0\\.009091199932382915\ \(0\)\
\-\ neoplastic\\:\\ 0\\.009091199932382915\ \(0\)\
\-\ possibly\\:\\ 0\\.009091199932382915\ \(0\)\
\-\ dominant\\:\\ 0\\.009066883841399148\ \(0\)\
\-\ on\\:\\ 0\\.009029825518071868\ \(0\)\
\-\ neural\\:\\ 0\\.008995596786350018\ \(0\)\
\-\ adult\\:\\ 0\\.008904197361358092\ \(0\)\
\-\ help\\:\\ 0\\.008859961605750432\ \(0\)\
\-\ progression\\:\\ 0\\.00883819175155647\ \(0\)\
\-\ destruction\\:\\ 0\\.008774217409213948\ \(0\)\
\-\ interval\\:\\ 0\\.008712153036761386\ \(0\)\
\-\ disease\\:\\ 0\\.008711460756023102\ \(0\)\
\-\ interstitial\\:\\ 0\\.008691869928766867\ \(0\)\
\-\ soft\\:\\ 0\\.008652502137187318\ \(0\)\
\-\ 17\\:\\ 0\\.008651887887336748\ \(0\)\
\-\ mediastinum\\:\\ 0\\.008555172678116594\ \(0\)\
\-\ disorders\\:\\ 0\\.008499232027555422\ \(0\)\
\-\ tissue\\:\\ 0\\.008421709723295609\ \(0\)\
\-\ noted\\:\\ 0\\.008421709723295609\ \(0\)\
\-\ steroids\\:\\ 0\\.00835702261615334\ \(0\)\
\-\ or\\:\\ 0\\.008328671509053701\ \(0\)\
\-\ discussion\\:\\ 0\\.008322939851546945\ \(0\)\
\-\ \\%\\:\\ 0\\.008288237144889845\ \(0\)\
\-\ origin\\:\\ 0\\.00814486200419041\ \(0\)\
\-\ regions\\:\\ 0\\.008129404668457524\ \(0\)\
\-\ idiopathic\\:\\ 0\\.008098830557460236\ \(0\)\
\-\ so\\:\\ 0\\.008083710475694998\ \(0\)\
\-\ as\\:\\ 0\\.008061813966075642\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.008024306374979704\ \(0\)\
\-\ lower\\:\\ 0\\.007991110475525417\ \(0\)\
\-\ important\\:\\ 0\\.00798084133377531\ \(0\)\
\-\ until\\:\\ 0\\.007802335532098819\ \(0\)\
\-\ either\\:\\ 0\\.007737563873512965\ \(0\)\
\-\ extends\\:\\ 0\\.007699647891080988\ \(0\)\
\-\ near\\:\\ 0\\.007687161354573271\ \(0\)\
\-\ described\\:\\ 0\\.007566255075660435\ \(0\)\
\-\ findings\\:\\ 0\\.007562731541746194\ \(0\)\
\-\ function\\:\\ 0\\.007531313041738645\ \(0\)\
\-\ \\(\\:\\ 0\\.007508957653262584\ \(0\)\
\-\ ct\\:\\ 0\\.007455116341322513\ \(0\)\
\-\ caused\\:\\ 0\\.007451995440981105\ \(0\)\
\-\ pa\\:\\ 0\\.007429878188995542\ \(0\)\
\-\ \\)\\:\\ 0\\.007417231726749534\ \(0\)\
\-\ nodule\\:\\ 0\\.007322689395513527\ \(0\)\
\-\ occurs\\:\\ 0\\.007291581552110797\ \(0\)\
\-\ pathology\\:\\ 0\\.007271098607322832\ \(0\)\
\-\ initially\\:\\ 0\\.007230728366455676\ \(0\)\
\-\ 25\\:\\ 0\\.007181343572260027\ \(0\)\
\-\ considered\\:\\ 0\\.00717160583980176\ \(0\)\
\-\ to\\:\\ 0\\.007103003882627631\ \(0\)\
\-\ symptomatic\\:\\ 0\\.007058177598116866\ \(0\)\
\-\ use\\:\\ 0\\.007021702941877968\ \(0\)\
\-\ is\\:\\ 0\\.007014022183593252\ \(0\)\
\-\ change\\:\\ 0\\.006924576903276181\ \(0\)\
\-\ malignancy\\:\\ 0\\.006865051305200657\ \(0\)\
\-\ process\\:\\ 0\\.006840052983024355\ \(0\)\
\-\ skin\\:\\ 0\\.006823552879914716\ \(0\)\
\-\ vomiting\\:\\ 0\\.006782866609240917\ \(0\)\
\-\ lungs\\:\\ 0\\.0067272112224122165\ \(0\)\
\-\ course\\:\\ 0\\.006703807574751854\ \(0\)\
\-\ has\\:\\ 0\\.0066723491496643575\ \(0\)\
\-\ view\\:\\ 0\\.0066653776066144255\ \(0\)\
\-\ occur\\:\\ 0\\.0066653776066144255\ \(0\)\
\-\ abnormalities\\:\\ 0\\.006525498174008767\ \(0\)\
\-\ above\\:\\ 0\\.006511306978436209\ \(0\)\
\-\ involvement\\:\\ 0\\.006511306978436209\ \(0\)\
\-\ reported\\:\\ 0\\.006476247090594204\ \(0\)\
\-\ later\\:\\ 0\\.006414591769216058\ \(0\)\
\-\ involving\\:\\ 0\\.006233694935557784\ \(0\)\
\-\ in\\:\\ 0\\.006132600022831153\ \(0\)\
\-\ thickening\\:\\ 0\\.006022088502480981\ \(0\)\
\-\ masses\\:\\ 0\\.006005389600823466\ \(0\)\
\-\ available\\:\\ 0\\.005972388874926814\ \(0\)\
\-\ density\\:\\ 0\\.0058453874362992915\ \(0\)\
\-\ bilaterally\\:\\ 0\\.005835146026037221\ \(0\)\
\-\ body\\:\\ 0\\.005769779028459636\ \(0\)\
\-\ should\\:\\ 0\\.005663635222222038\ \(0\)\
\-\ further\\:\\ 0\\.005649572020374758\ \(0\)\
\-\ radiographs\\:\\ 0\\.00562634270520194\ \(0\)\
\-\ known\\:\\ 0\\.0056217278263281075\ \(0\)\
\-\ adjacent\\:\\ 0\\.005617123168678311\ \(0\)\
\-\ any\\:\\ 0\\.005594251628008927\ \(0\)\
\-\ frontal\\:\\ 0\\.005580648512439413\ \(0\)\
\-\ 1\\.\\:\\ 0\\.0055492498259825385\ \(0\)\
\-\ clinical\\:\\ 0\\.005466340540677764\ \(0\)\
\-\ severe\\:\\ 0\\.005466340540677764\ \(0\)\
\-\ show\\:\\ 0\\.005453546641354732\ \(0\)\
\-\ usually\\:\\ 0\\.005394861234650227\ \(0\)\
\-\ no\\:\\ 0\\.005366595534535148\ \(0\)\
\-\ demonstrated\\:\\ 0\\.005212931356459392\ \(0\)\
\-\ evaluation\\:\\ 0\\.005160579617103551\ \(0\)\
\-\ wall\\:\\ 0\\.00514586095683731\ \(0\)\
\-\ y\\.o\\:\\ 0\\.0051276079679557175\ \(0\)\
\-\ s\\:\\ 0\\.0050951510750823015\ \(0\)\
\-\ region\\:\\ 0\\.0050178819693125\ \(0\)\
\-\ history\\:\\ 0\\.0049073369551230085\ \(0\)\
\-\ shows\\:\\ 0\\.004884352806089146\ \(0\)\
\-\ been\\:\\ 0\\.004833253408449046\ \(0\)\
\-\ common\\:\\ 0\\.004649204182861533\ \(0\)\
\-\ these\\:\\ 0\\.0046233777379580876\ \(0\)\
\-\ for\\:\\ 0\\.004547452070536685\ \(0\)\
\-\ both\\:\\ 0\\.004536798317434764\ \(0\)\
\-\ over\\:\\ 0\\.00452316546806645\ \(0\)\
\-\ more\\:\\ 0\\.0044431939902539845\ \(0\)\
\-\ consistent\\:\\ 0\\.004356129457029529\ \(0\)\
\-\ associated\\:\\ 0\\.004192229858435971\ \(0\)\
\-\ 3\\:\\ 0\\.004160032280055176\ \(0\)\
\-\ most\\:\\ 0\\.004101528361181031\ \(0\)\
\-\ other\\:\\ 0\\.004094882637635028\ \(0\)\
\-\ it\\:\\ 0\\.003993447784891926\ \(0\)\
\-\ exam\\:\\ 0\\.003902773263928354\ \(0\)\
\-\ have\\:\\ 0\\.003847064611985638\ \(0\)\
\-\ but\\:\\ 0\\.003788988151836877\ \(0\)\
\-\ multiple\\:\\ 0\\.0037418004230338232\ \(0\)\
\-\ the\\:\\ 0\\.0037364671541520486\ \(0\)\
\-\ female\\:\\ 0\\.003652308256648303\ \(0\)\
\-\ also\\:\\ 0\\.0035023276375678826\ \(0\)\
\-\ that\\:\\ 0\\.0030685670032407973\ \(0\)\
\-\ by\\:\\ 0\\.0029581515659976606\ \(0\)\
\-\ of\\:\\ 0\\.0029065397288479443\ \(0\)\
\-\ there\\:\\ 0\\.0026438992857899975\ \(0\)\
\-\ from\\:\\ 0\\.0026329224805700883\ \(0\)\
\-\ and\\:\\ 0\\.0026196736800946554\ \(0\)\
\-\ a\\:\\ 0\\.002473595437538054\ \(0\)\
\-\ an\\:\\ 0\\.002456683709531663\ \(0\)\
\-\ are\\:\\ 0\\.0024217752027642448\ \(0\)\
\-\ with\\:\\ 0\\.002189267328085255\ \(0\)\
\-\ \\.\\:\\ 0\\.001992697452449791\ \(0\)\
\-\ year\\:\\ 0\\.0019877448425632323\ \(0\)\
\-\ right\\:\\ 0\\.0018744941977347541\ \(0\)\
\-\ patient\\:\\ 0\\.0017808564052315759\ \(0\)\
